Team members for the OmniaBio
Brian Walsh is a highly skilled sales leader with over 25 years of experience driving growth in CRO/CDMO services and commercial products. His expertise spans the entire drug discovery, development, and manufacturing lifecycle. Before joining OmniaBio, Brian served as SVP of Business Development at Cellipont, where he played a key role in global revenue growth […]
Neil Blackburn earned his PhD from the University of Guelph, where he focused on protein biochemistry and immunology. His post-doctoral training at Eli Lilly and Company focused on dendritic cell tolerization and the interaction of immune cells with novel TLR ligands. Neil next led the development and commercialization of immunochemical-based clinical assays and companion medical devices
Neil Blackburn, Ph.D. Read More »
For over 20 years, Dr. Jessica Tate has been at the forefront of viral vector research, pioneering groundbreaking advancements in the gene therapy industry. With a Ph.D. in molecular genetics from the University at Buffalo, she has leveraged her extensive expertise to facilitate the progression of more than 70 viral vector products, four of which
Jessica Tate, Ph.D. Read More »
Ken Harris has dedicated over three decades to revolutionizing health care. With a profound expertise spanning 35 years in the field, Ken has been at the forefront of innovation and leadership in technology, medical devices and therapeutics. In his most recent role, Ken spearheaded the academic medicine and public health vertical within Amazon’s $90 billion
Tony is an Executive leader with 46 years of pharmaceutical manufacturing expertise that covers building facilities, optimizing operations, and supporting therapeutics developers from clinical to commercial scale. With deep experience in all facets of operations, revenue growth, and quality assurance,Tony has developed a strong track record in ensuring company and client success, with proven turnaround
Jason Cervi has spent over 20 years in financial leadership roles in highly regulated industries including health care, medical devices, medical cannabis and aerospace and defense with large global publicly listed organizations with market capitalizations up to USD $15B. Most recently, Jason was the CFO of Atlas Global Brands Inc, a producer and international distributor
Mitch Sivilotti is a respected leader in the Life Sciences industry and serves as the President and Chief Executive Officer of OmniaBio Inc., a CDMO serving the cell and gene therapy market. Most recently, Mitch was the Chief Operating Officer at CCRM, a Toronto-based cell and gene therapy (CGT) accelerator focused on cell therapy and
